Literature DB >> 10711243

Discovering novel chemotherapeutic drugs for the third millennium.

M D Garrett1, P Workman.   

Abstract

There is enormous potential for the discovery of innovative cancer drugs with improved efficacy and selectivity for the third millennium. In this review we show how novel mechanism-based agents are being discovered by focusing on the molecular targets and pathways that are causally involved in cancer formation, maintenance and progression. We also show how new technologies, from genomics through high through-put bioscience, combinatorial chemistry, rational drug design and molecular pharmacodynamic and imaging techniques, are accelerating the pace of cancer drug discovery. The process of contemporary small molecule drug discovery is described and progress and current issues are reviewed. New and potential targets and pathways for therapeutic intervention are illustrated. The first examples of a new generation of molecular therapeutics are now entering hypothesis-testing clinical trials and showing activity. The early years of the new millennium will see a range of exciting new agents moving from bench to bedside and beginning to impact on the management and cure of cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10711243     DOI: 10.1016/s0959-8049(99)00280-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  16 in total

Review 1.  A new paradigm for the development of anticancer agents from natural products.

Authors:  Balanehru Subramanian; Alexander Nakeff; Karen Tenney; Phillip Crews; Leslie Gunatilaka; Fred Valeriote
Journal:  J Exp Ther Oncol       Date:  2006

Review 2.  The changing role of pathology in breast cancer diagnosis and treatment.

Authors:  Anthony S-Y Leong; Zhengping Zhuang
Journal:  Pathobiology       Date:  2011-06-14       Impact factor: 4.342

3.  Metal ion-mediated polymer superquenching for highly sensitive detection of kinase and phosphatase activities.

Authors:  Frauke Rininsland; Wensheng Xia; Shannon Wittenburg; Xiaobo Shi; Casey Stankewicz; Komandoor Achyuthan; Duncan McBranch; David Whitten
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-19       Impact factor: 11.205

4.  Growth inhibition, G(1)-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives.

Authors:  Juan Antonio Marchal; Houria Boulaiz; Inés Suárez; Estrella Saniger; Joaquín Campos; Esmeralda Carrillo; José Prados; Miguel Angel Gallo; Antonio Espinosa; Antonia Aránega
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

5.  Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility.

Authors:  Neal B Blatt; Jeffrey J Bednarski; Roscoe E Warner; Francesco Leonetti; Kathryn M Johnson; Anthony Boitano; Raymond Yung; Bruce C Richardson; Kent J Johnson; Jonathan A Ellman; Anthony W Opipari; Gary D Glick
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

6.  Synthesis of novel 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole derivatives as antiproliferative agents: a structure-activity relationship study.

Authors:  S B Benaka Prasad; K Vinaya; C S Ananda Kumar; Sanjay Swarup; K S Rangappa
Journal:  Invest New Drugs       Date:  2008-12-06       Impact factor: 3.850

7.  British Cancer Research Meeting 2001. Leeds, United Kingdom, 1-4 July 2001. Abstracts.

Authors: 
Journal:  Br J Cancer       Date:  2001-07       Impact factor: 7.640

8.  Diagnosis of drug-induced renal tubular toxicity using global gene expression profiles.

Authors:  Ying Jiang; David L Gerhold; Daniel J Holder; David J Figueroa; Wendy J Bailey; Ping Guan; Thomas R Skopek; Frank D Sistare; Joseph F Sina
Journal:  J Transl Med       Date:  2007-10-01       Impact factor: 5.531

Review 9.  The future of cytotoxic therapy: selective cytotoxicity based on biology is the key.

Authors:  Johann S de Bono; Anthony W Tolcher; Eric K Rowinsky
Journal:  Breast Cancer Res       Date:  2003-03-27       Impact factor: 6.466

10.  Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin.

Authors:  D Liu; O C Hutchinson; S Osman; P Price; P Workman; E O Aboagye
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.